My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC   - Episode 6

Use of Combination Regimens in Frontline RCC

,

Martin H. Voss, MD, presents data supporting the use of various combination regimens in the frontline treatment of renal cell carcinoma (RCC), focusing on the pivotal trials such as CheckMate 214, KEYNOTE 426, and the CLEAR trial, emphasizing their respective efficacy, safety, and overall impact on the current treatment landscape for RCC patients.

  1. Please review data supporting the use of other combination regimens in frontline RCC.
    • CheckMate 214 (nivo +ipi): Tannir, et al. ASCO GU 2024. Abstract 363
    • KEYNOTE 426 (axi +pembro): Plimack ER, et al. Eur Urol. 2023)
    • CLEAR (len+pem vs sunitinib): Viktor Grunwald et. al, ASCO 2024, Abstract 4524